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ABSTRACT 
Design of vesicles as a tool to enhance drug delivery has created a lot of interest among humans operating within drug delivery systems space 
over the past decade. Niosomes are formations of vesicles by a hydrating mixture of cholesterol and nonionic surfactants. Completely different 
novel approaches used to deliver these medicines include liposomes, microspheres, engineering science, small emulsions, antibody-loaded drug 
delivery, magnetic microcapsules, implantable pumps and niosomes. Design and development of novel drug delivery system (NDDS) has two 
prerequisites. First, it should distribute the drug in accordance with a predetermined rate and second it should release therapeutically effective 
amount of drug at the site of action. Conventional dosage forms are unable to meet these requisites. Niosomes are basically non-ionic surfactant 
based vesicles in which an aqueous solution of solute is completely sealed off by a membrane resulting from the group of surfactant 
macromolecules as bilayer. Niosomes remain in the bloodstream for a reasonable time, which is useful for targeted drug delivery. This review 
additionally presents an overview of the strategies of preparation of niosome, types of niosomes, characterization and their applications.  
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Present investigation and development strategy focus on 
progress of drug delivery systems that make clinically 
established drugs do their therapeutic best rather than 
search for new drugs. The aim of any drug delivery system 
should always be to achieve maximum therapeutic response 
with minimum side effects. Like phospholipids, the nonionic 
surfactants are able to form vesicular delivery systems called 
“niosomes” when dispersed in water. This is a rather recent 
concept with a few but very important investigations which 
show that carrier system possesses great potential in 
delivery of drugs in biological system. They are known to be 
analogous to liposomes, and have been used in cosmetic 
formulations and experimentally as drug carriers 1, 2, 3. 
Niosomal vesicles are able to encapsulate both lipophilic and 
hydrophilic drugs and protect them against acidic and 
enzymatic effects in vivo3. They deals with several 
advantages over liposomes such as higher chemical stability, 
intrinsic skin penetration enhancing the properties and 
lower costs 4. However, there may be problems of physical 
instability in niosome dispersions during storage like 
vesicles aggregation, fusion, leaking or hydrolysis of 
encapsulated drugs, which might affect the shelf life of the 
dispersion 5.  In recent years, niosomes have been 
extensively studied for their potential to serve as a carrier 
for the delivery of drugs, antigens, hormones and other 
bioactive agents. Above and beyond this, niosomes have been 
used to solve the problem of insolubility, instability and 
rapid degradation of drugs 6. 
Advantages of Niosomes  
1. Niosomes can offer control and sustained release 
system of drugs. 
2. Improve oral bioavailability. 
3. Niosomes can be designed according to the desired 
situation because of its flexibility in their structural 
characteristics (composition, fluidity and size). 
4. Therapeutically can be increased if the drug is 
incorporate in Niosomes. Niosomes can accommodate 
variety of drug moieties such as hydrophilic, 
5. Effective permeation of drugs into cells  
6. Prolongation of existence of drugs in systemic 
circulation.  
7. Delayed elimination of rapidly metabolized drugs.  
8. Overcomes the problems of the drug insolubility, 
instability, and rapid degradations.  
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9. Performances can be improved by restricting effects to 
target cells and protecting drugs from biological 
environment 7. 
10. Niosomes are osmotically active and stability of 
entrapped drug can be increased by niosomal 
preparation. 
11. Niosomes can enhance the skin penetration of drug 
through skin 
12. They offer to reach the drug at the site of action by 
multiple routes such as oral, parenteral as well as 
topical routes. 
13. Surfactants used in Niosomes are non-immunogenic, 
biodegradable and biocompatible. 
14. No special conditions are not required for handling and 
storage of surfactants 8. 
15. As selective uptake is taken place so reduces toxicity.  
16. Reduces the cost of therapy.  
17. Niosomes are colloidal vesicular carriers and these 
vesicles can act as drug reservoirs and the rate of drug 
release can be modified by changing of their 
composition. 
18. Niosomes can encapsulate both hydrophilic drugs (by 
loading in inner space) and hydrophobic drugs (in lipid 
area). That’s why it is used in various drug delivery 
systems like drug targeting, controlled release and 
permeation enhancement of drugs 9. 
Disadvantages of Niosomes 
Along with numbers of advantages of Niosomes, have some 
serious disadvantages which restrict their use. Drugs 
passively , which may lead to low drug loading efficiency and 
drug leakage in preparation, preservation and transport in 
vivo. Need of intensive sonication, lead to leakages of drug 
during storage. Thus the major problem of their stability acts 
as a barrier and thus limiting their use 10- 13. 
 
Figure1. Structure of Niosomes containing Hydrophilic and 
Hydrophobic layer of drug molecule 
 
COMPONENTS USED IN THE PREPARATION OF 
NIOSOMES 
Niosomes mainly contains following types of components: 
Non-ionic Surfactants  
The non-ionic surfactants orient themselves in bilayer 
lattices where the polar or hydrophobic heads align facing 
aqueous bulk (media) while the hydrophobic head or 
hydrocarbon segments align in such a way that the 
interaction with the aqueous media would be minimized. To 
attain thermodynamic stability, every bilayer folds over itself 
as continuous membrane i.e. forms vesicles so that 
hydrocarbon/water interface remains no more exposed 14. 
Mainly following types of non-ionic surfactants are used for 
the formation of niosomes: 
Alkyl Ethers: L’Oreal described some surfactants14 for the 
preparation of niosomes containing drugs/ chemicals as 
i. Surfactant-I (molecular weight (MW 473)) is C16 
monoalkyl glycerol ether with average of three glycerol 
units. 
ii. Surfactant-II (MW 972) is diglycerol ether with average 
of the seven glycerol units. 
iii. Surfactant III (MW 393) is ester linked surfactant. 
Other than alkyl glycerol, alkyl glycosides and alkyl ethers 
bearing polyhydroxyl head groups are also used in 
formulation of niosomes14, 15, 16. 
Alkyl Esters: Sorbitan esters are most preferred surfactant 
used for the preparation of niosomes amongst this category 
of surfactants 17, 18. Vesicles prepared by the polyoxyethylene 
sorbitan monolaurate are relatively soluble than other 
surfactant vesicles 19. For example polyoxyethylene 
(polysorbate 60) has been utilized for encapsulation of 
diclofenac sodium11. A mixture of polyoxyethylene-10-
stearyl ether: glyceryl laurate: cholesterol (27: 15: 57) has 
been used in transdermal delivery of cyclosporine-A 14, 21. 
Alkyl Amides: Alkyl amide (e.g. galactosides and glucosides) 
have been utilized to produce niosomal vesicles 22. 
Fatty Acid and Amino Acid Compounds: Long chain fatty 
acids and amino acid moieties have also been used in some 
niosomes preparation 23. 
Cholesterol  
Steroids are important components of the cell membrane 
and their presence in membrane affect the bilayer fluidity 
and permeability. Cholesterol is a steroid derivative, which is 
mainly used for the formulation of niosomes. Although it may 
not show any role in the formation of bilayer, its importance 
in formation of niosomes and manipulation of layer 
characteristics cannot be discarded. In general, incorporation 
of cholesterol affects properties of niosomes like membrane 
permeability, rigidity, encapsulation efficiency, ease of 
rehydration of freeze dried Niosomes and their toxicity. It 
prevents the vesicle aggregation by the inclusion of 
molecules that stabilize the system against the formation of 
aggregates by repulsive steric or electrostatic forces that 
leads to the transition from the gel to the liquid phase in 
niosome systems. As a result of this, the noisome becomes 
less leaky in nature 24. 
Charged Molecule  
Some charged molecules are added to niosomes to increase 
stability of niosomes by electrostatic repulsion which 
prevents coalescence. The negatively charged molecules 
used are diacetyl phosphate (DCP) and phosphotidic acid. 
Similarly, stearylamine (STR) and stearyl pyridinium 
chloride are the well-known positively charged molecules 
used in niosomal preparations. These charged molecules are 
used mainly to prevent aggregation of Niosomes 25. Only 2.5-
5 mol percentage concentration of charged molecules is 
tolerable because high concentration can inhibit the niosome 
formation 26, 27.  
TYPES OF NIOSOMES 
Niosomes can be divided into following two types:- 
On the basis of their vesicles size:  
1. Small Uni-lamellar Vesicles (SUV, Size=0.025-0.05 µm)  
2.  Multi-lamellar Vesicles (MLV, Size=>0.05 µm)  
3. Large Uni-lamellar Vesicles (LUV, Size=>0.10 µm).14 
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Figure 2. Schematic structures of non-ionic surfactant 
vesicle. (a) Uni-lamellar vesicle, (b,c). Multi-lamellar vesicle. 
On the basis of material used:  
1. Bola surfactant containing niosomes: The surfactant 
use in Bola surfactant containing niosomes are made of 
omega hexadecylbis-(1-aza-18 crown-6) (bola 
surfactant): span- 80/cholesterol in 2:3:1 molar ratio 
28, 29. 
2. Proniosomes: Proniosomes are the niosomal 
formulation containing carrier and surfactant, which 
requires to be hydrated before being used. The 
hydration results in the formation of aqueous niosome 
dispersion. Proniosomes decreases the aggregation, 
leaking and fusion problem associated with niosomal 
formulation 30. 
3. Aspasomes: Aspasomes is produced using the mix of 
acorbylpalmitate cholesterol and exceptionally charged 
lipid diacetyl phosphate prompts the arrangement of 
vesicles. Aspasomes are first hydrated with water/fluid 
arrangement and afterward it is subjected to sonication 
to get the niosomes. Aspasomes can be utilized to build 
the transdermal saturation of medications. Aspasomes 
have likewise been utilized to diminish scatter caused 
by responsive oxygen species as it has in cell 
reinforcement property. 
4. Niosomes in carbopolgel: Niosomes were prepared 
from drug, spans and cholesterol then it is incorporated 
in carbopol-934 gel (1%w/w) base containing 
propylene glycol (10% w/w) and glycerol (30% w/w). 
5. Vesicles in water and oil system (v/w/o): In this 
strategy, the aqueous niosomes into an oil stage frame 
vesicle in water in oil emulsion (v/w/o). This can be set 
up by expansion of niosomes suspension figured from 
blend of sorbitol monostearate, cholesterol and solulan 
C24 (Poly-24-Oxyethylene cholesteryl ether) to oil 
stage at 60 0C. This result in the formation of vesicle in 
water in oil (v/w/o) emulsion which by cooling to 
room temperature forms vesicle in water in oil gel 
(v/w/o gel). The v/w/o gel thus obtained can entrap 
proteins/ proteinous drugs and also protect it from 
enzymatic degradation after oral administration and 
controlled release. 
6. Niosomes of hydroxyl propyl methyl cellulose: In 
this type, a base containing 10% glycerin of hydroxyl 
propyl methyl cellulose was first prepared and then 
niosomes were incorporated in it 31, 32. 
7. Deformable niosomes: The mixture of non-ionic 
surfactants, ethanol and water forms the deformable 
niosomes. These are smaller vesicles and easily pass 
through the pores of stratum corneum, which leads to 
increase penetration efficiency. It can be used in topical 
preparation 33, 34. 
 
FACTORS AFFECTING TO NIOSOMES 
FORMULATION 
1. Drug: Entrapment of drug in niosomes increases 
vesicle size, probably by interaction of solute with 
surfactant head groups, increasing the charge and 
mutual repulsion of the surfactant bilayers, thereby 
increasing vesicle size. In polyoxyethylene glycol (PEG) 
coated vesicles. 
2. Amount and type of surfactant: The mean size of 
niosomes increases proportionally with increase in the 
HLB surfactants like Span 85 (HLB 1.8) to Span 20 (HLB 
8.6) because the surface free energy decreases with an 
increase in hydrophobicity of surfactant. The bilayers 
of the vesicles are either in the so-called liquid state or 
in gel state, depending on the temperature, the type of 
lipid or surfactant and the presence of other 
components such as cholesterol Phase transition 
temperature (TC) of surfactant also effects entrapment 
efficiency i.e. Span 60 having higher TC, provides better 
entrapment. 
3. Cholesterol content and charge: Inclusion of 
cholesterol in niosomes increased its hydrodynamic 
diameter and entrapment efficiency. In general, the 
action of cholesterol is two folds; on one hand, 
cholesterol increases the chain order of liquid-state 
bilayers and on the other, Cholesterol decreases the 
chain order of gel state bilayers. At a high cholesterol 
concentration, the gel state is transformed to a liquid 
ordered phase presence of charge tends to increase the 
interlamellar distance between successive bilayers in 
multilamellar vesicle structure and leads to greater 
overall entrapped volume. 
4. Resistance to osmotic stress: Addition of a hypertonic 
salt solution to a suspension of niosomes brings about 
reduction in diameter. In hypotonic salt solution, there 
is initial slow release with slight swelling of vesicles 
probably due to inhibition of eluting fluid from vesicles, 
followed by faster release, which may be due to 
mechanical loosening of vesicles structure under 
osmotic stress. 
5. Membranes Composition: The stable niosomes can be 
prepared with addition of different additives along 
with surfactants and drugs. Niosomes formed have a 
number of morphologies and their permeability and 
stability properties can be altered by manipulating 
membrane characteristics by different additives. In 
case of polyhedral niosomes formed from C16G2, the 
shape of these polyhedral noisome remains unaffected 
by adding low amount of solulan C24 (cholesterol poly-
24- oxyethylene ether), which prevents aggregation 
due to development of stearic unhydrance. In contrast 
spherical Niosomes are formed by C16G2: cholesterol: 
solution (49:49:2) 35-37. 
6. Nature of encapsulated drug: The physico-synthetic 
properties of typified medicate impact charge and 
unbending nature of the niosome bilayer. The 
medication cooperates with surfactant head gatherings 
and builds up the charge that makes shared a version 
between surfactant bilayers and subsequently expands 
vesicle estimate. The aggregation of vesicles is 
prevented due to the charge development on bilayer. 
7. Temperature of hydration: Hydration temperature 
influences the shape and size of the niosome, 
temperature change of niosomal system affects 
assembly of surfactants into vesicles by which induces 
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vesicle shape transformation. Ideally the hydration 
temperature for niosome formation should be above 
the gel to liquid phase transition temperature of system 
38. 
8. Structure of surfactants: The geometry of vesicle to 
be shaped from surfactants is influenced by surfactant’s 
structure, which can be characterized by basic pressing 
parameters. Geometry of vesicle to be shaped can be 
predicated on the premise of basic pressing parameters 
of surfactants. Critical packing parameters can be 
defined using following equation, 
CPP (Critical Packing Parameters) =V/lc × a0 
Where,      V = hydrophobic group volume, 
lc = the critical hydrophobic group len gth, 
a0= the area of hydrophilic head group. 
Critical packing parameter value type of miceller structure 
formed can be ascertained as given below, If CPP < ½ 
formation of spherical micelles, If ½ < CPP < 1 formation of 
bilayer micelles, If CPP > 1 formation inverted micelles 39. 
METHOD OF PREPRATION OF NIOSOMES 
The preparation method of niosomes affects the size, size 
distribution, number of bilayers, and entrapment efficiency 
of the aqueous phase and the membrane permeability of the 
vesicles. It also depends on the use of niosomes. 
1. Ether injection method: In this method a solution of 
surfactant dissolved in diethyl ether into warm water 
maintained at 60°C by slowly. Using a 14-gauge needle, 
the surfactant mixture in ether is injected into an 
aqueous solution of material. Single layered vesicles are 
formed after vaporization of ether 40. 
2. Sonication Method: Sonication is a typical method for 
the production of vesicles. In this method a mixture is 
prepared by adding drug solution in buffer into the 
surfactant cholesterol which can be taken in 10-ml 
glass vial. Using a sonicator this mixture is sonicated at 
60°C for 3 minutes with a titanium probe to yield 
niosomes 41. 
3. Micro fluidization Method: Recently, Micro 
fluidization method is used to prepare unilamellar 
vesicles of defined size distribution. This method works 
according to the submerged jet principle. According to 
this principle two fluidized streams interact at ultra-
high velocities, in precisely defined micro channels 
within the interaction chamber. The energy supplied to 
the system remains within the area where niosomes is 
formed. The impingement of thin liquid sheet along a 
common front is arranged in such a way that the 
energy is supplied only the niosomes forming area. A 
greater uniformity, smaller size and better 
reproducibility of niosomes is formed by this method 
42. 
4. Multiple membrane extrusion method: A thin film is 
made from the mixture of surfactant, cholesterol and 
dicetyl phosphatein chloroform by evaporation. The 
film is hydrated with aqueous drug polycarbonate 
membranes, solution and the resultant suspension 
extruded through which are placed in series for upto 8 
passages. Niosome size is suitably controlled by this 
method 43. 
5. Reverse Phase Evaporation Technique (REV): 
Cholesterol and surfactant (1:1) are dissolved in a 
mixture of ether and chloroform. Then aqueous phase 
which contain drug is added to the mixture. Final 
mixture contains two phases that are sonicated at 4-5 
°C. The clear gel is formed where small amount of 
phosphate buffered saline (PBS) is added here then 
further sonicated. After sonication organic phase is 
removed at 40 °C under low pressure. The resulting 
viscous noisome suspension is diluted with PBS and 
heated on a water bath at 60 °C for 10 min to yield 
niosomes 44. 
6. Hand shaking method (thin film hydration 
technique): Surfactant and cholesterol are dissolved in 
a volatile organic solvent (diethyl either, chloroform or 
methanol) in a round bottom flask. A thin layer of solid 
mixture deposited on the wall of the flask after 
removing organic solvent at room temperature (20 °C) 
using rotary evaporator the dried The dried surfactant 
film can be rehydrated with aqueous phase at 0-60 °C 
with gentle agitation. Typical multilamellar niosomes is 
formed by this process 45.  
7. Transmembrane pH gradient Drug Uptake Process 
(Remote Loading): A solution of surfactant and 
cholesterol is made in chloroform. A thin film on the 
wall of the round bottom flask is formed after 
evaporating the solvent under reduced pressure, 
similar to the hand shaking method. Hydration of this 
solution is done by using citric acid solution with help 
of vortex mixing. Multilamellar vesicles are formed 
then treated to three freeze thaw cycles and sonicated.  
Aqueous solution containing 10 mg/ml of drug is added 
to the niosomal suspension and vortexed. 1M disodium 
phosphate is used to raise the pH of the sample to 7.0-
7.2 and mixture is later heated at 60 °C for 10 minutes 
to give niosomes 46.   
8. The “Bubble” Method: Recently the “Bubble” method 
has been developed and this method allows the 
preparation of niosomes without the use of organic 
solvents. The bubbling unit consists of a round bottom 
flask with three necks which is placed in a water bath 
to control the temperature. Among the three necks, 
water cooled reflux and thermometer is positioned in 
the first and second neck and the third neck is used to 
supply nitrogen. Cholesterol and surfactant are 
dispersed together in a buffer (pH 7.4) at 70 °C and 
mixed for a period of 15 seconds with high shear 
homogenizer and immediately afterwards, it is bubbled 
at 70 °C using the nitrogen gas to yield niosomes 47.   
9. Formation of Niosomes from Proniosomes: 
Proniosome is a dry formulation in which each water-
soluble particle was covered with a thin film of dry 
surfactant. The niosomes were recognized by the 
adding aqueous phase at T > Tm with brief agitation. T 
is the Temperature and Tm is the mean phase 
transition temperature 48. 
10. Method of Handjani: The equivalent amounts of 
synthetic non-ionic lipids were mixed with the aqueous 
solution of active substance that was encapsulated. 
Homogenous lamellar film was formed through 
shaking.Using ultra-centrifugation and agitation, the 
resultant mixture was then homogenized at a 
controlled temperature 49.   
11. Micro fluidization Method: Micro fluidization is a 
recent technique used to prepare unilamellar vesicles 
of defined size distribution. This method is based on 
submerged jet principle in which two fluidized streams 
interact at ultra-high velocities, in precisely defined 
micro channels within the interaction chamber. The 
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impingement of thin liquid sheet along a common front 
is arranged such that the energy supplied to the system 
remains within the area of niosomes formation. The 
result is a greater uniformity, smaller size and better 
reproducibility of niosomes formed 50.  
PHARMACEUTICAL APPLICATION OF NIOSOMES 
The application of niosomal technology is widely varied and 
can be used to treat a number of diseases. 
1. Niosomes as Drug Carriers: Niosomes have also been 
used as carriers for iobitridol, a diagnostic agent used 
for X-ray imaging. Topical niosomes may serve as 
solubilization matrix, as a local depot for sustained 
release of dermally active compounds, as penetration 
enhancers, or as rate-limiting membrane barrier for the 
modulation of systemic absorption of drugs. 
2. Drug Targetting: One of the most useful aspects of 
niosomes is their ability to target drugs. Niosomes can 
be used to target drugs to the reticuloendothelial 
system. The reticulo-endothelial system (RES) 
preferentially takes up niosome vesicles. The uptake of 
niosomes is controlled by circulating serum factors 
called opsonins. These opsonins mark the niosome for 
clearance. Such localization of drugs is utilized to treat 
tumors in animals known to metastasize to the liver 
and spleen. This localization of drugs can also be used 
for treating parasitic infections of the liver. Niosomes 
can also be utilized for targeting drugs to organs other 
than the RES. A carrier system (such as antibodies) can 
be attached to niosomes (as immunoglobulin’s bind 
readily to the lipid surface of the niosome) to target 
them to specific organs. 
3. Anti-neoplastic Treatment: Most antineoplastic drugs 
cause severe side effects. Niosomes can alter the 
metabolism; prolong circulation and half-life of the 
drug, thus decreasing the side effects of the drugs. 
Niosomes are decreased rate of proliferation of tumor 
and higher plasma levels accompanied by slower 
elimination. 
4. Leishmaniasis: Leishmaniasis is a disease in which a 
parasite of the genus Leishmania invades the cells of 
the liver and spleen. Use of niosomes in tests conducted 
showed that it was possible to administer higher levels 
of the drug without the triggering of the side effects, 
and thus allowed greater efficacy in treatment. 
5. Delivery of Peptide Drugs: Oral peptide drug delivery 
has long been faced with a challenge of bypassing the 
enzymes which would breakdown the peptide. Use of 
niosomes to successfully protect the peptides from 
gastrointestinal peptide breakdown is being 
investigated. In an in vitro study conducted by oral 
delivery of a vasopressin derivative entrapped in 
niosomes showed that entrapment of the drug 
significantly increased the stability of the peptide. 
6. Use in Studying Immune Response: Due to their 
immunological selectivity, low toxicity and greater 
stability; niosomes are being used to study the nature 
of the immune response provoked by antigens. 
Nonionic surfactant vesicles have clearly demonstrated 
their ability to function as adjuvant following 
parenteral administration with a number of different 
antigens and peptides. 
7. Niosomes as Carriers for Haemoglobin: Niosomes 
can be used as carriers for haemoglobin within the 
blood. The niosomal vesicle is permeable to oxygen and 
hence can act as a carrier for haemoglobin in anaemic 
patients 51-54. 
8. Cancer therapy: The drugs that are mostly used in the 
cancer therapy through Niosomal drug delivery are 
Doxorubicin HCL, Methotextrate, Bleomycin, 
Vincristine, Daunorubicin HCL. The side effect of 
Doxorubicin when administered as a free drug is 
cardiac toxicity, whereas when administered as a 
niosomal formulation the cardiac toxicity was reduced. 
By niosomal formulation, doxorubicin has increased 
level in tumor cells, serum and lungs. It also reduces 
the proliferation rate of tumor cells and increases the 
life span of tumor bearing mice. Methotrexate 
entrapped by nisomes gives higher plasma level and 
also increase the half-life of drug which gives prolonged 
action of the drug i.e, it will have slower elimination of 
drug. 
9. As carrier: Niosomes being the vesicles can easily 
permeate to oxygen and the hemoglobin dissociation 
curve is modifiedsimilarly to non-encapsulated 
hemoglobin. So they are used as the carrier for 
haemoglobin 55. 
10. Pre-oral delivery: The drugs which are degraded by 
the proteolytic enzymes and gastric juices cannot be 
administered orally. This can be modified by a 
niosomal formulation. Eg: Insulin is a peptide hormone 
which balances the glucose level in the body. It cannot 
be administered orally because it gets degraded by the 
proteolytic enzymes in the stomach. Niosomes protects 
the insulin from degradation by its bilayer formation 56. 
11. Leishmaniasi: Niosomes can be used in treatment of 
diseases of reticuloendothelial system. Leishmaniasis is 
one of the disease in which the protozoan parasites 
invades the liver and the spleen cells. It is treated using 
antimonials. These drugs as free drug cannot give 
increased plasma levels. Sodium stibogluconate 
niosomal formulation of anit-monials can permeate 
through the cells and target the specific cells. Thus 
niosomes can be used in drug targeting 57. 
12. Transdermal drug delivery: The delivery of drugs 
through skin indicates the transdermal drug delivery. 
The advantages of this delivery are it does not undergo 
first-pass metabolism. At the same time, the drawback 
of this delivery is the penetration of drugs is slow 
through skin. The skin acts as the barrier for the 
penetration of drugs this drawback can be overcome by 
the niosomal preparation. The mechanism followed by 
the niosomes for transdermal drug delivery is:  
 Diffusion through stratum corneum layer.  
 The amount of water present in the skin is 
important for this mechanism.  
 The lipophilic drugs cross the stratum corneum 
by aggregation, fusion and adhesion. 
 The niosomes loses the cells of stratum corneum 
which increases the permeation of drugs. 
 The non-ionic surfactant enhances the 
permeation and this leads to improved drug 
permeation through skin 58, 59.   
13. Niosomes as carrier in dermal drug delivery: 
Niosomes were used for the dermatological purpose in 
1975 in cosmetic industry. The first niosomal cosmetic 
product was launched by Lancome Niosome – an 
antiaging formulation. Topical formulations of 
niosomes which are developed recently are mentioned 
below.  
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14. Local anesthesia: Absence of sensation is induced by 
local anesthetics through topical preparation. The 
penetration of drug is low through skin, so niosomes 
acts as a carrier to improve the penetration of drug by 
entrapping them in vesicles which moves through the 
skin easily. Lidocaine hydrochloride a local anesthetic 
prepared by niosomes i.e, lidocane entrapped with 
tween 20 and cholesterol showed better performance 
compared with liposomes 60. 
15. Psoriasis: Psoriasis is a dermal disorder, caused by a 
T-lympocytemediated autoimmune disease of dermis 
and epidermis. It is a chronic inflammatory condition of 
skin. It forms scaling erythematous plagues on skin. 
The patient suffers from itching, painful and disfiguring 
skin lesions. The drugs which are used topically for the 
treatment of Psoriasis are Anthralin, Methotrexate, 
Corticosteriods, VitD3, coal tar, Tacrolimus. 
Methotrexate is an anti-cancer drug used in the 
treatment of psoriasis, when administered systemically 
it leads to several adverse effects one which is 
hepatotoxicity. So, topical application can be selected as 
an alternate to reduce the adverse effects. The niosomal 
chitosin Methotrexate gel shows 3 times reduction in 
lesion after 12 weeks. Thus niosomal Methotrexate gel 
can be used in topical treatment of psoriasis 61. 
CHARACTERIZATION OF NIOSOMES 
1. Size: Shape of niosomal vesicles is assumed to be 
spherical, and their mean diameter can be determined by 
using laser light scattering method. Also, diameter of 
these vesicles can be determined by using electron 
microscopy, molecular sieve chromatography, 
ultracentrifugation, photon correlation microscopy, 
optical microscopy and freeze fracture electron 
microscopy. Freeze thawing (keeping vesicles suspension 
at 20 °C for 24 hrs and then heating to ambient 
temperature) of Niosomes increases the vesicle diameter, 
which might be attributed to fusion of vesicles during the 
cycle 62. 
2. Stability study: Stability studies are done by storing 
niosome at two different conditions, usually 4±1 0C and 
25±2 0C. Formulation size, shape and number of vesicles 
per cubic mm can be assessed before and after storing for 
30 days. After 15 and 30 days, residual drug can also be 
measured. Light microscope is used for determination of 
size of vesicles and the numbers of vesicles per cubic mm 
is measured by haemocytometer 63, 64. 
Number of niosomes per cubic mm = Total number of 
niosomes x dilution factor x 400/ Total number of small 
squares counted 
3. Vesicular surface charge: Niosomes are generally 
prepared by the inclusion of charged molecules in bilayer 
to prevent the aggregation of vesicles 65. A reduction in 
aggregate formation was observed when charged 
molecule like dicetyl phosphate was incorporated in 
vesicles. The chargeon vesicles is expressed in terms of 
zeta potential and calculated using the Henry’s equation 
66, 67. 
£ =μEπη /Σ 
Where, 
£ - Zeta potential 
μE - Electrophoretic mobility 
η - Viscosity of medium 
Σ - Dielectric constant 
4. Bilayer Formation: Assembly of non-ionic surfactants to 
form a bilayer vesicle is characterized by an X-cross 
formation under light polarization microscopy 68. 
5. Number of Lamellae: This is determined by using 
nuclear magnetic resonance (NMR) spectroscopy, small 
angle X-ray scattering and electron microscopy 69. 
6. Membrane Rigidity: The mobility of fluorescence probe 
as a function of temperature has been used for the 
determination of membrane rigidity of some niosomal 
formulations. Membrane rigidity can be measured by 
means of mobility of fluorescence probe as a function of 
temperature 70. 
7. Entrapment Efficiency: drug is separated by dialysis, 
centrifugation, or gel filtration as described above and 
the drug remained entrapped in Niosomes is determined 
by complete vesicle disruption using 50% n-propanol or 
0.1% Triton X-100 and analyzing the resultant solution 
by appropriate assay method for the drug71.  
Drug Entrapment efficiency = (Amount entrapped / total 
amount) x 100. 
a. In-Vitro Release Study: A method of in vitro release rate 
study has been reported with the help of dialysis tubing. 
A dialysis sac is washed and soaked in distilled water. 
The vesicle suspension is pipetted into a bag made up of 
the tubing and sealed. The bag containing the vesicles is 
then placed in 200 ml buffer solution in a 250 ml beaker 
with constant shaking at 25 °C or 37 °C. At various time 
intervals, the buffer is analyzed for the drug content by 
an appropriate assay method. In another method, 
isoniazid-encapsulated niosomes are separated by gel 
filtration on Sephadex G-50 powder kept in double 
distilled water for 48 h for swelling. At first, 1 ml of 
prepared niosome suspension is placed on the top of the 
column and elution is carried out using normal saline. 
Niosomes encapsulated isoniazid elutes out first as a 
slightly dense, white opalescent suspension followed by 
free drug. Separated niosomes are filled in a dialysis tube 
to which a sigma dialysis sac is attached to one end. The 
dialysis tube is suspended in phosphate buffer of pH 7.4, 
stirred with a magnetic stirrer, and samples are 
withdrawn at specific time intervals and analyzed using 
high-performance liquid chromatography (HPLC) 
method 71, 72. 
b. In Vivo Release Study: Albino rats are used for this 
study. These rats are subdivided with groups. Niosomal 
suspension used for in vivo study is injected 
intravenously (through tail vein) using appropriate 
disposal syringe 71, 72. 
CONCLUSION 
For decades, pharmaceutical sciences have been utilizing 
nanoparticles to reduce harmfulness and side impacts of 
drugs. Niosomal drug delivery systems to be favourable 
controlled drug delivery systems to the target area. 
Niosomes are composed mainly of non-ionic surfactants and 
cholesterol.  Niosomes are relatively non-toxic and stable 
and offer successful drug localization in skin. Physical and 
chemical instability of active drug can be protected by 
vesicular carriers. The properties of Niosomes are affected 
by additives, methods of preparation, drug properties, 
amount, structure and type of surfactant used, cholesterol 
content and resistance to osmotic stress. In nutshell, as a 
drug delivery device, compared to liposomes, niosomes are 
osmotically active and are quite stable chemically by their 
own as well as improve the stability of the drug so entrapped 
and delivered. Among the all of these points of interest there 
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are still a few challenges in this range. The sort of surfactant 
is the most parameter since it influences the arrangement of 
the vesicles, their poisonous quality and soundness. So 
the specialists should be more alert within the choice of 
appropriate surfactant for niosome arrangement.  
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